Devicemakers won’t have to stage new clinical trials of their devices to gain approval in China if they can demonstrate that they’re basically equivalent to devices already on the market, Chinese regulators say.
The treatment market value for fibromyalgia across the seven major markets will reach $1.9...
This year, many Afghan poppy farmers are expecting a windfall as they get ready to harvest opium...
The global treatment market value for prostate cancer will expand more than threefold by 2023....
Many so-called cancer hotels dot the neighborhoods around Chinese hospitals, giving patients an affordable, cozy place to wait for appointments and undergo outpatient treatment.
Merck is introducing Clinical Diabetes management for more than 5000 medical students in 18 medical colleges of Maharashtra University as part of Merck Capacity Advancement Program (CAP) in Asia.
Microbix Biosystems has signed an exclusive distribution agreement with Kim & Friends, Inc. The agreement provides Microbix with improved access to the key South Korean market for its virology products.
Simulations Plus announced that several regulatory agencies around the world have added licenses of software for pharmaceutical discovery and development within the past three months.
Pfizer has stopped selling its Prevnar 7 pneumonia vaccine in China after its import license expired, but the U.S. drugmaker still intends to launch the world's most widely used vaccine, Prevnar 13, in that market.
Takeda will use ImmunoGen's technology to develop cancer treatments. ImmunoGen will get $20 million upfront and is eligible for milestone payments potentially totaling up to $210 million, plus royalties on sales.
A recent report from research firm GlobalData predicted Japan will see a "tepid" recovery in its pharmaceutical market over the next several years. The London-based firm estimates Japan’s pharmaceutical market will climb from $72.8 billion in 2013 to $79.8 billion by 2020, a Compound Annual Growth Rate of 1.3 percent.
Takeda Pharmaceutical Co., Japan's largest drug company, has expanded its Singapore operations by relocating its emerging markets business unit to the city-state from Zurich, executives said at an inauguration ceremony Wednesday.
The analysis by New York-based Persistence Market Research predicted Vitamin D supplements would lead the growth in the industry over that span. The report expects increasing geriatric populations, particularly in Asia, to bolster demand for Vitamin D.
Mylan announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of Sovaldi and Harvoni for the treatment of chronic hepatitis C, in India.
Health authorities were working to ensure remote hospitals in northern and western India had adequate medical supplies for a flu outbreak that has claimed more than 700 lives in 10 weeks.
The Chinese treatment market for colorectal cancer (CRC) will expand almost fourfold in value from an estimated $259 million in 2013 to $1.05 billion by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 15.1%, according to research and consulting firm GlobalData.
Merck has announced that the company and Bristol-Myers Squibb have agreed to transfer full responsibility for the promotion of Erbitux® (cetuximab) to Merck in Japan as of May 1, 2015
The United States has accused the Chinese government of providing prohibited subsidies on a wide range of the country's exports, providing an unfair advantage in the marketplace and hindering American businesses.
The single use bioreactors (SUBs) market is expected to grow at a double digit CAGR of 18.4% to reach $470.9 million by 2019 from $202.5 million in 2014. Developing markets such as China and India are lucrative markets for single-use bioreactors (SUB), owing to the low cost benefits offered by these nations.
A number of medicines for which authorization in the European Union (EU) was primarily based on clinical studies conducted at GVK Biosciences in Hyderabad, India should be suspended, says the European Medicines Agency (EMA).
Catalent Pharma Solutions and Mitsubishi Gas Chemical Company, Inc. (MGC), have entered into a partnership agreement to co-promote Catalent’s proprietary GPEx® technology in the Asian market.
Roche, Meiji Seika Pharma and Fedora have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development. Under the agreement, Roche obtains worldwide rights from both companies for development and commercialization with the exception of Japan, where Meiji will retain sole commercialization rights.
This action comes in light of recent information from a trusted regulatory partner that raises concerns about the reliability of the laboratory data generated at these sites. Health Canada is taking this action as an interim precautionary measure to help mitigate any potential risk.
Pharmaceutical Product Development and Shin Nippon Biomedical Labs have formed a joint venture that will provide a full range of clinical development services in Japan, including Phase I-IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory and FSP services.
Sartorius, an international laboratory and pharmaceutical equipment provider, is selling its Industrial Technologies Division (Intec) to the Japanese Minebea Co., Ltd. (Minebea) and their partner, the Development Bank of Japan Inc.
Two former Eli Lilly and Co. employees who were accused of sending trade secrets worth more than $55 million to a competing Chinese drug company will no longer face charges, the U.S. attorney's office announced Friday.
The Age-related Macular Degeneration treatment market across seven major countries (the US, UK, Germany, France, Spain, Italy and Japan) will almost double in value from $5.1 billion in 2013 to $10.1 billion by 2023, according to research and consulting firm GlobalData.
Otsuka Pharmaceutical will spend $3.5 billion in cash to buy Avanir Pharmaceuticals in a deal that expands the Japanese drugmaker's portfolio of neurologic disease treatments. Avanir shareholders will receive $17 per share, according to the agreement announced Tuesday.
Vetter has announced the opening of a new representative office in Singapore. The announcement was made at a ceremony attended by members of local government agencies and a number of executives of pharmaceutical/biotech companies with a presence in the Asian region, as well as Vetter executives.
- Page 1